1-(2,2,2-trifluoroethyl)azetidine-3-carboxylic acid | 1339115-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 1-(2,2,2-trifluoroethyl)azetidine-3-carboxylic acid
• CAS: 1339115-53-5
• 化学式: C₆H₈F₃NO₂
• mdl: MFCD20282477
• 分子量: 183.13
• InChiKey: JNYQZTQYRYZPSA-UHFFFAOYSA-N

物化性质

• 沸点：
  204.0±40.0 °C(Predicted)
• 密度：
  1.427±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(2,2,2-trifluoroethyl)azetidine-3-carboxylic acid 、 tert-butyl (2R,5S)-5-[2-(4-chloro-3-fluorophenoxy)acctamido]-2-(hydrazinecarbonyl)piperidine-1-carboxylate 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.17h， 生成 tert-butyl (2R,5S)-5-[2-(4-chloro-3-fluorophenoxy)acetamido]-2-{N'-[1-(2,2,2-trifluoroethyl)azetidine-3-carbonyl]hydrazinecarbonyl}piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY
  [FR] MODULATEURS DE LA VOIE DE RÉPONSE AU STRESS INTÉGRÉE

  摘要：

  本发明涉及具有式（I）的化合物或其药学上可接受的盐、溶剂化合物、水合物、互变异构体或立体异构体，其中R1、R2、R2a、R3、Ra2、Ra4、Ra5、Ra6、Ra7、X1、X1a、A1和A2的含义如描述和权利要求中所示。该发明还涉及包含所述化合物的药物组合物，其用作药物以及用于治疗和预防与整合应激反应相关的一种或多种疾病或紊乱的方法。

  公开号：

  WO2020216766A1

文献信息

• SGC stimulators
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US11180493B2

  公开（公告）日：2021-11-23

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

  本公开涉及可溶性鸟苷酸环化酶（sGC）的刺激剂、包含它们的药物制剂及其单独或与一种或多种附加制剂组合的用途，用于治疗各种疾病，其中一氧化氮（NO）浓度的增加和/或环磷酸鸟苷（cGMP）浓度的增加可能是可取的。本文公开了多种化合物，包括式（I）化合物。
• SGC STIMULATORS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20200071318A1

  公开（公告）日：2020-03-05

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).
• sGC STIMULATORS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20220017515A1

  公开（公告）日：2022-01-20

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:
• MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY
  申请人：EVOTEC INTERNATIONAL GMBH

  公开号：US20220227747A1

  公开（公告）日：2022-07-21

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R 1 , R 2 , R 2a , R 3 , R a2 , R a4 , R a5 , R a6 , R a7 , X 1 , X 1a , A 1 and A 2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.
• [EN] SGC STIMULATORS<br/>[FR] STIMULATEURS DE SGC
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2018089330A2

  公开（公告）日：2018-05-17

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).